Home > Press > Novel Gold-Nanoparticle-Based Assay for Understanding Alzheimer’s Disease
Abstract:
Acetylcholinesterase (AChE) is an enzyme that can catalytically break down acetylcholine at cholinergic synapses, resulting in the termination of synaptic transmission. It had been shown that the level of AChE in the cerebrospinal fluid of individuals suffering from Alzheimer's disease is significantly reduced. Therefore, a low level of AChE may indicate a risk or a preclinical stage of Alzheimer's disease. This information could be useful for early prevention and treatment of the disease. However, to date there is no accurate method for identifying Alzheimer's disease in an early or asymptomatic stage of the disease.
The clinical application of existing gold nanoparticle (AuNP)-based colorimetric assays is hampered by their moderate sensitivity and selectivity. Now, however, Xingyu Jiang and co-workers (National Center for Nanoscience and Technology, Beijing) have developed a novel AuNP-based assay highly sensitive to acetylcholinesterase (AChE). The fluorescence of Rhodamine B detached from Au surfaces is measured and simultaneously the color change of AuNPs solutions is known.
This new assay provides a detection limit (0.1 mU/mL) much lower than that of all existing probes for AChE. Such a high sensitivity allows the measurement of AChE in the cerebrospinal fluid even after being diluted more than a thousand times. In this manner, false positive results for other components like biothiols in real samples can be ruled out and relevant clinical tests are rendered possible. The study shows that the level of AChE in model mice that suffer from Alzheimer's disease (AD) is lower than that in healthy mice. The assay also allows the progression of the disease and the effect of drug treatments to be studied by monitoring the AChE level in the model mice treated with different drug dosages.
####
For more information, please click here
Copyright © Wiley-VCH Materials Science Journals
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related Links |
Dingbin Liu et al., Adv. Healthcare Mat. ; DOI: 10.1002/adhm.201100002
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Discoveries
Breaking carbon–hydrogen bonds to make complex molecules November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||